PDCD1 and neoplasm: When the TME of peritoneal tumors was analyzed, the combination therapy increased the number of tumor-infiltrating CD8+ T cells by 6.77-fold, whereas anti-PD-1 and JX monotherapy increased infiltrating CD8+ T cells by 2-fold and 5.94-fold, respectively, when compared with the controls.